Valuation: Milestone Pharmaceuticals Inc.

Market Cap 166M 143M 134M 122M 231M 15.86B 232M 1.58B 614M 8B 624M 611M 26.48B P/E 2026 *
-1.4x
P/E 2027 * -1.41x
Enterprise Value 166M 143M 134M 122M 231M 15.86B 232M 1.58B 614M 8B 624M 611M 26.48B EV / Sales 2026 *
43.4x
EV / Sales 2027 * 7.51x
Free-Float
99.3%
Yield 2026 *
-
Yield 2027 * -
1 day+1.72%
1 week+10.28%
Current month+6.31%
1 month+1.72%
3 months-16.31%
6 months-31.79%
Current year-41.58%
1 week 1.02
Extreme 1.02
1.19
1 month 1.01
Extreme 1.01
1.29
Current year 1
Extreme 1
2.34
1 year 1
Extreme 1
3.06
3 years 0.63
Extreme 0.6254
3.52
5 years 0.63
Extreme 0.6254
9.85
10 years 0
Extreme 0
27.95
Manager TitleAgeSince
Chief Executive Officer 59 2017-03-06
Director of Finance/CFO 53 2019-09-08
Compliance Officer 48 2026-02-09
Director TitleAgeSince
Director/Board Member 59 2017-06-30
Director/Board Member 60 2019-03-31
Director/Board Member 67 2020-09-30
Date Insider Type Main position Quantity % Market Cap.
6/10/26 Free

Director

77,000 0.0618%
2/2/26 Free

Chief Operating Officer

204,000 0.2395%
2/2/26 Free

Chief Executive Officer

679,000 0.7972%
Change 5-day change 1-year change 3-year change Capi.($)
+1.72%+10.28%-30.18%-58.60% 163M
+3.31%-3.70%+61.03%+103.64% 71.35B
+2.09%+3.17%+52.14%+91.30% 64.17B
-1.31%+21.36%+7.13%-4.29% 28.65B
+0.40%-3.17%-3.06%+469.55% 27.06B
-2.78%+4.47%+52.49%+14.43% 27.33B
-1.68%+2.61%+37.12%-16.09% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
-0.57%-4.06%+10.79%+515.61% 15.96B
-1.09%+5.61%+48.02%+155.12% 14.05B
Average +0.10%+4.86%+50.49%+169.10% 28.86B
Weighted average by Cap. +0.78%+3.32%+55.70%+154.00%

Financials

2026 *2027 *
Net sales 3.83M 3.29M 3.08M 2.82M 5.31M 365M 5.33M 36.47M 14.15M 184M 14.37M 14.06M 610M 22.14M 19M 17.82M 16.28M 30.72M 2.11B 30.83M 211M 81.81M 1.07B 83.12M 81.3M 3.53B
Net income -117M -100M -93.99M -85.87M -162M -11.14B -163M -1.11B -431M -5.62B -438M -429M -18.59B -131M -112M -105M -96.26M -182M -12.48B -182M -1.25B -484M -6.3B -491M -481M -20.84B
Net Debt - -
Logo Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Employees
38
Date Price Change Volume
26-08-26 US$1.180 +1.72% 726,234
26-08-25 US$1.160 +11.54% 1,709,324
26-08-24 US$1.040 -1.42% 1,562,343
26-08-21 US$1.055 +2.43% 1,916,948
26-08-20 US$1.030 -4.63% 2,177,519
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.180USD
Average target price
5.857USD
Spread / Average Target
+396.37%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MIST Stock